A New Initiative to Identify and Manage Drug Risks
Boli Zhang,Youping Li
DOI: https://doi.org/10.1111/j.1756-5391.2010.01071.x
2010-01-01
Journal of Evidence-Based Medicine
Abstract:Health is a basic human right as defined by the World Health Organization (WHO), and it must be shared by everyone. “Health for All in 2020” is the solemn promise of all United Nations member governments to the WHO, the United Nations, and their citizens, and it must be fulfilled before the due date. As medical workers, we are all too aware that we have not enough approaches to many diseases, including chronic cardiovascular and cerebrovascular diseases, endocrine and metabolic diseases, and cancer. We have seen an upward trend in incidences of trauma, toxication, pain and neuropsychiatric disorders, and various acute and chronic infectious diseases. Moreover, the therapeutic effect of many available drugs is limited, the long-term safety record is alarming, and over-use coexists with under-use. We also have to recognize the need to analyze and reevaluate widely-used therapeutic strategies and drugs with various problems, and to identify the best therapies and cease use of those that are not as safe, effective, or cost-effective This is true for all therapies, whether the originated in the East or in the West. In view of the increasing number of post-market Western medicine found to carry unacceptable risks of adverse drug reactions or adverse events (ADR/AEs), and of Chinese Medicine Injections (CMIs) removed from the market and investigated, experts from the Chinese Evidence-Based Medicine Center, Sichuan University, Tianjin University of Traditional Chinese Medicine—Branch Center of Virtual Research Center of Evidence-based Medicine of Ministry of Education, and the School of Chinese Medicine of the Hong Kong Baptist University organized a transdisciplinary team to carry out a series of rigorous and well-designed studies. These studies were published in the Chinese Journal of Evidence-Based Medicine and received extensive attention. Based on a systematic review of ADR/AE reports for 33 CMIs included in the National Essential Medicine List 2004 (NEML 2004), we quantified the risks of ADR/AE for each kind of CMI. Our research included risk surveillance and management, secondary research with available literature, primary research on key issues, policy and practice translational research, and performance evaluation research, for each high-risk CMI. We are now initiating a special column on these reviews in both this journal and the Chinese Journal of Evidence-Based Medicine. Both columns will be available for free download, and we hope they will attract attention, suggestions, and participation from researchers at home and abroad. In this issue we present the first of these manuscripts in this special series: a commentary by Prof. Dequan Ren, former deputy director-general of the State Administration of Traditional Chinese Medicine of the People's Republic of China; a systematic review of ADR/AEs for all 33 CMIs listed in NEML 2004; and analysis of the quality of reports of CMI-associated ADR/AE reports (using Yuxingcao Injection as an example) and a proposed ADR/AE reporting standard for traditional Chinese medicine (TCM); the laws for use of CMI; and systematic reviews of ADR/AE reports for high-risk CMIs Shuanghuanglian injection, Qingkailing injection, Yuxingcao injection, and Ciwujia injection. As a well-known Chinese saying says, “Someone has failed, others are going forward”. We believe that the gradually in-depth, evidence-based exploration of CMI-associated ADR/AEs will boost modern TCM research and development, and will contribute to the development of the subject, team, and industry of modern TCM.